Interleukin-12 gene therapy of a weakly immunogenic mouse mammary carcinoma results in reduction of spontaneous lung metastases via a T-cell- independent mechanism

Cancer Gene Therapy

Volumn 7, Issue 6, 2000, Pages 826-838

  Rakhmilevich, Alexander L ^a,b   Janssen, Karen ^c   Hao, Zhengling ^b   Sondel, Paul M ^a,b   Yang, Ning Sun ^b  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF WISCONSIN   (United States)

^c Argracetus Inc   (United States)

Author keywords

Cytokines; Gene therapy; In vivo animal models; Tumor immunity

Indexed keywords

COMPLEMENTARY DNA; GAMMA INTERFERON; INTERLEUKIN 12;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CARCINOMA; CONTROLLED STUDY; GENE TARGETING; GENE THERAPY; IMMUNOGENICITY; IN VIVO STUDY; LUNG METASTASIS; METASTASIS INHIBITION; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL;

ANIMALIA; MURINAE; MUS MUSCULUS;

EID: 0033933974     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700176     Document Type: Article

References (51)

1. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1998. CA Cancer J Clin. 1998;48:6-29.
2. Disis ML, Calenoff E, McLaughlin G, et al. Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer. Cancer Res. 1994;54:16-20.
3. Tilkin AF, Lubin R, Soussi T, et al. Primary proliferative T cell response to wild-type p53 protein in patients with breast cancer. Eur J Immunol. 1995;25:1765-1769.
4. Constantin GI, Fisk B, Jerome KR, et al. Cytotoxic T cells from ovarian malignant tumors can recognize polymorphic epithelial mucin core peptides. J Immunol. 1993;151:3693-3703.
5. Apostolopoulos V, McKenzie IF, Pietersz GA. Breast cancer immunotherapy: current status and future prospects. Immunol Cell Biol. 1996;74:457-464.
6. Pardoll DM. Paracrine cytokine adjuvants in cancer immunotherapy. Annu Rev Immunol. 1995;13:399-415.
7. Colombo MP, Modesti A, Parmiani G, Forni G. Local cytokine availability elicits tumor rejection and systemic immunity through granulocyte-T-lymphocyte cross-talk. Cancer Res. 1992;52:4853-4857.
8. Bubenik J. Cytokine gene-modified vaccines in the therapy of cancer. Pharmacol Ther. 1996;69:1-14.
9. + T cells against wild-type tumor: correlation with antigen presentation capability. J Exp Med. 1992;175:1423-1431.
10. Bannerji R, Arroyo CD, Cordon-Cardo C, Gilboa E. The role of IL-2 secreted from genetically modified tumor cells in the establishment of antitumor immunity. J Immunol. 1994;152:2324-2332.
11. Porgador A, Tzehoval E, Katz A, et al. Interleukin 6 gene transfection into Lewis lung carcinoma tumor cells suppresses the malignant phenotype and confers immunotherapeutic competence against parental metastatic cells. Cancer Res. 1992;52:3679-3686.
12. Dranoff G, Jaffee E, Lazenby A, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA. 1993;90:3539-3543.
13. Brunda MJ, Gately MK. Interleukin-12: potential role in cancer therapy. Important Adv Oncol. 1995:3-18.
14. Brunda MJ, Luistro L, Warrier RR, et al. Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J Exp Med. 1993;178:1223-1230.
15. Nastala CL, Edington HD, McKinney TG, et al. Recombinant IL-12 administration induces tumor regression in association with IFN-γ production. J Immunol. 1994;153: 1697-1706.
16. Zou J-P, Yamamoto N, Fujii T, et al. Systemic administration of rIL-12 induces complete tumor regression and protective immunity: response is correlated with a striking reversal of suppressed IFN-γ production by anti-tumor T cells. Int Immunol. 1995;7:1135-1145.
17. Mu J, Zou JP, Yamamoto N, et al. Administration of recombinant interleukin 12 prevents outgrowth of tumor cells metastasizing spontaneously to lung and lymph nodes. Cancer Res. 1995;55:4404-4408.
18. Marshall E. Cancer trial of interleukin-12 halted. Science. 1995;268:1555.
19. Cohen J. IL-12 deaths: explanation and a puzzle. Science. 1995;270:908.
20. Rakhmilevich AL, Turner J, Ford MJ, et al. Gene gun-mediated skin transfection with interleukin 12 gene results in regression of established primary and metastatic murine tumors. Proc Natl Acad Sci USA. 1996;93:6291-6296.
21. Rakhmilevich AL, Janssen K, Turner J, Culp J, Yang N-S. Cytokine gene therapy of cancer using gene gun technology: superior antitumor activity of interleukin-12. Hum Gene Ther. 1997;8:1303-1311.
22. Nanni P, De Giovanni C, Lollini P-L, Nicoletti G, Prodi G. TS/A: a new metastasizing cell line from a BALB/c spontaneous mammary adenocarcinoma. Clin Exp Metastasis. 1983;1:373-380.
23. Giovarelli M, Santoni A, Forni G. Alloantigen-activated lymphocytes from mice bearing a spontaneous nonimmunogenic adenocarcinoma inhibit its growth in vivo by recruiting host immunoreactivity. J Immunol. 1985;133: 3596-3603.
24. Allione A, Consalvo M, Nanni P, et al. Immunizing and curative potential of replicating and nonreplicating murine mammary adenocarcinoma cells engineered with interleukin (IL)-2, IL-4, IL-6, IL-10, tumor necrosis factor α, granulocyte-macrophage colony-stimulating factor, and γ-interferon gene or admixed with conventional adjuvants. Cancer Res. 1994;54:6022-6026.
25. Aslakson CJ, Miller FR. Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res. 1992;52:1399-1405.
26. Wexler H. Accurate identification of experimental pulmonary metastases. J Natl Cancer Inst. 1966;36:641-645.
27. Gately MK, Warrier RR, Honasoge S, et al. Administration of recombinant IL-12 to normal mice enhances cytolytic lymphocyte activity and induces production of IFN-γ in vivo. Int Immunol. 1994;6:157-167.
28. Brunda MJ, Luistro J, Hendrzak JA, et al. Role of interferon-γ in mediating the antitumor efficacy of interleukin-12. J Immunother. 1995;17:71-77.
29. Scott OCA. Tumor transplantation and tumor immunity: a personal view. Cancer Res. 1991;3:326-333.
30. Hewitt HB, Blake ER, Walder AS. A critique of the evidence for active host defense against breast cancer, based on personal studies of 27 murine tumours of spontaneous origin. Br J Cancer. 197;33:241-256.
31. Wang RF, Rosenberg SA. Human tumor antigens recognized by T lymphocytes: implications for cancer therapy. J Leukoc Biol. 1996;60:296-309.
32. Coulie PG. Human tumour antigens recognized by T cells: new perspectives for anti-cancer vaccines? Mol Med Today. 1997;3:261-268.
33. Disis ML, Cheever MA. HER-2/neu protein: a target for antigen-specific immunotherapy of human cancer. Adv Cancer Res. 1997;71:343-371.
34. Stern LL, Tarby CM, Tamborini B, Truitt GA. Preclinical development of IL-12 as an anticancer drug: comparison to IL-2. Proc Am Assoc Cancer Res. 1994;35:520.
35. Lamont AG, Adorini L. IL-12: a key cytokine in immune regulation. Immunol Today. 1996;17:214-217.
36. Coughlin CM, Wysocka M, Trinchieri G, Lee WMF. The effect of interleukin 12 desensitization on the antitumor efficacy of recombinant interleukin 12. Cancer Res. 1995; 55:4980-4987.
37. Rakhmilevich AL, Timmins JG, Janssen K, et al. Gene gun-mediated IL-12 gene therapy induces antitumor effects in the absence of toxicity: a direct comparison with systemic IL-12 protein therapy. J Immunother. 1999;22: 135-144.
38. Colombo MP, Vagliani M, Spreafico F, et al Amount of interleukin 12 available at the tumor site is critical for tumor regression. Cancer Res. 1996;56:2531-2534.
39. Martinotti A, Stoppacciaro A, Vagliani M, et al. CD4 T cells inhibit in vivo the CD8-mediated immune response against murine colon carcinoma cells transduced with interleukin-12 genes. Eur J Immunol. 1995;25:137-146.
40. Chen L, Chen D, Block E, et al. Eradication of murine bladder carcinoma by intratumor injection of a bicistronic adenoviral vector carrying cDNAs for the IL-12 heterodimer and its inhibition by the IL-12 p40 subunit homodimer. J Immunol. 1997;159:351-359.
41. + T lymphocytes in the primary and memory response to nonimmunogenic murine mammary adenocarcinoma made immunogenic by IL-2 gene. J Immunol. 1992;149:3627-3635.
42. Golumbek PT, Lazenby AJ, Levitsky HI, et al. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science. 1991;254:713-716.
43. Cavallo F, Di Carlo E, Butera M, et al. Immune events associated with the cure of established tumors and spontaneous metastases by local and systemic interleukin 12. Cancer Res. 1999;59:414-421.
44. Chan SH, Perussia B, Gupta JW, et al. Induction of interferon γ production by natural killer cell stimulatory factor: characterization of the responder cells and synergy with other inducers. J Exp Med. 1991;173:869-873.
45. Smithson G, Bittick TH, Chervenak R, Lee S-J, Wolcott RM. The role of NK cells in the regulation of experimental metastasis in a murine lymphoma system. J Leukoc Biol. 1991;49:621-629.
46. Yao L, Sgadari C, Furuke K, et al. Contribution of natural killer cells to inhibition of angiogenesis by interleukin-12. Blood. 1999;93:1612-1621.
47. Bramson JL, Hitt M, Addison CL, et al. Direct intratumoral injection of an adenovirus expressing interleukin-12 induces regression and long-lasting immunity that is associated with highly localized expression of interleukin-12. Hum Gene Ther. 1996;7:1995-2002.
48. Voest EE, Kenyon BM, O'Reilly MS, et al. Inhibition of angiogenesis in vivo by interleukin 12. J Natl Cancer Inst. 1995;87:581-586.
49. Dias S, Boyd R, Balkwill F. IL-12 regulates VEGF and MMPs in a murine breast cancer model. Int J Cancer. 1998;78:361-365.
50. Sgadari C, Angiolillo AL, Tosato G. Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10. Blood. 1996;87:3877-3882.
51. Coughlin CM, Salhany KE, Wysocka M, et al. Interleukin-12 and interleukin-18 synergistically induce murine tumor regression which involves inhibition of angiogenesis. J clin Invest. 1998;101:1441-1452.